Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ursodeoxycholic acid (UDCA), also known as ursodiol or 熊脱氧胆酸 in Chinese, is a naturally occurring secondary bile acid used primarily for the treatment of primary biliary cholangitis (PBC; formerly called primary biliary cirrhosis) and for the dissolution and prevention of cholesterol gallstones. It works by reducing the cholesterol saturation of bile and replacing more toxic hydrophobic bile acids in the bile pool. This leads to gradual dissolution of cholesterol-rich gallstones and reduces liver damage in cholestatic liver diseases. UDCA is also used off-label for other cholestatic conditions such as biliary atresia and intrahepatic cholestasis[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ursodeoxycholic acid.